NCT00253565View on ClinicalTrials.gov

Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2010

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

capecitabine

DRUG

imatinib mesylate

Trial Locations (1)

27710

Duke Comprehensive Cancer Center, Durham

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Herbert Hurwitz

OTHER

NCT00253565 - Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter